Rallybio (RLYB)
NASDAQ:RLYB
Want to see RLYB full AI Analyst Report?
Top Page
Rallybio
(NASDAQ:RLYB)
Select Model
Select Model
Rating:56Neutral
Price Target:
$15.00
▲(64.65% Upside)
Action:Reiterated
Date:06/02/26
The score is held back primarily by weak financial performance (pre-commercial losses and ongoing cash burn), despite a strong technical uptrend and positive, well-funded strategic transaction news. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield support.
Positive Factors
Low leverage / strong balance sheet
Very low debt and near-zero leverage materially reduce solvency risk and preserve flexibility to fund clinical programs via equity or partnerships. This structural strength lengthens runway options and lowers bankruptcy risk versus highly levered peers in biotech.
Negative Factors
Persistent pre-commercial losses
The company remains pre-commercial with ongoing negative operating and free cash flow, implying continual reliance on external capital. Over the medium term this elevates dilution and execution risk if clinical progress or financing windows underperform expectations.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt and near-zero leverage materially reduce solvency risk and preserve flexibility to fund clinical programs via equity or partnerships. This structural strength lengthens runway options and lowers bankruptcy risk versus highly levered peers in biotech.
Read all positive factors
Rallybio (RLYB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$85.83M
Dividend YieldN/A
Average Volume (3M)283.42K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth1.18%
EPS Growth83.26%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.49
Shares Outstanding5,298,137
10 Day Avg. Volume220,035
30 Day Avg. Volume283,421
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.53
Price to Sales (P/S)36.02
P/FCF Ratio-1.04
Enterprise Value/Market Cap0.41
Enterprise Value/Revenue41.34
Enterprise Value/Gross Profit41.48
Enterprise Value/Ebitda-1.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Rallybio Business Overview & Revenue Model
Company Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal ant...
How the Company Makes Money
null...
Rallybio Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 858.00K | 858.00K | 636.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 855.00K | 766.00K | 636.00K | -150.00K | -167.00K | -109.00K |
| EBITDA | -28.06M | -27.97M | -60.37M | -78.78M | -67.72M | -45.39M |
| Net Income | -7.82M | -8.98M | -57.77M | -74.56M | -66.65M | -47.01M |
Balance Sheet | ||||||
| Total Assets | 54.47M | 62.26M | 68.11M | 115.62M | 180.44M | 182.19M |
| Cash, Cash Equivalents and Short-Term Investments | 46.80M | 54.74M | 65.51M | 109.93M | 168.99M | 175.33M |
| Total Debt | 154.00K | 176.00K | 154.00K | 392.00K | 555.00K | 0.00 |
| Total Liabilities | 4.20M | 4.30M | 6.45M | 9.44M | 11.12M | 6.58M |
| Stockholders Equity | 50.28M | 57.96M | 61.65M | 106.18M | 169.32M | 175.60M |
Cash Flow | ||||||
| Free Cash Flow | -27.59M | -29.81M | -49.28M | -60.28M | -57.34M | -45.87M |
| Operating Cash Flow | -27.59M | -29.81M | -49.28M | -60.27M | -57.28M | -45.53M |
| Investing Cash Flow | 54.09M | 47.27M | 33.49M | 27.66M | -112.17M | -2.33M |
| Financing Cash Flow | 19.00K | 16.00K | 5.20M | 143.00K | 51.08M | 82.97M |
Rallybio Technical Analysis
Positive
9.11
Price Trends
11.53
Positive
9.20
Positive
7.12
Positive
Market Momentum
1.26
Positive
66.16
Neutral
55.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLYB, the sentiment is Positive. The current price of 9.11 is below the 20-day moving average (MA) of 14.95, below the 50-day MA of 11.53, and above the 200-day MA of 7.12, indicating a bullish trend. The MACD of 1.26 indicates Positive momentum. The RSI at 66.16 is Neutral, neither overbought nor oversold. The STOCH value of 55.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLYB.
Rallybio Risk Analysis
Rallybio disclosed 68 risk factors in its most recent earnings report. Rallybio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rallybio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $85.83M | -11.61 | -14.39% | ― | 1.18% | 83.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $27.05M | -2.29 | -112.05% | ― | ― | 94.17% | |
44 Neutral | $13.39M | -3.26 | ― | ― | ― | 80.65% | |
44 Neutral | $6.33M | -0.19 | -389.34% | ― | ― | 99.36% | |
44 Neutral | $16.18M | -0.27 | -67.42% | ― | ― | 55.15% | |
42 Neutral | $7.56M | -0.47 | -281.30% | ― | ― | 86.07% |
* Healthcare Sector Average
RLYB
Rallybio
15.95
12.95
432.02%
MBRX
Moleculin Biotech
2.40
-14.35
-85.67%
APVO
Aptevo Therapeutics
4.72
-79.52
-94.40%
CTXR
Citius Pharmaceuticals
0.56
-0.81
-59.12%
PCSA
Processa Pharmaceuticals
2.52
-5.60
-68.97%
ALLR
Allarity Therapeutics
1.61
0.73
82.95%
Rallybio Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Rallybio to Merge with Avenzo, Shifting to Oncology
Positive
Jun 1, 2026
On May 31, 2026, Rallybio agreed to acquire Avenzo Therapeutics in an all-stock merger that will leave Avenzo shareholders and new private investors owning about 97.2% of the combined company, while existing Rallybio holders will retain roughly 2....
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
Rallybio Receives Termination Fee After Candid Deal Collapse
Neutral
May 4, 2026
On March 1, 2026, Rallybio Corporation signed a Merger Agreement to acquire Candid Therapeutics via a wholly owned subsidiary, but Candid terminated the deal on May 3, 2026 after entering an alternative agreement with UCB S.A. As a result of the t...
Executive/Board ChangesM&A Transactions
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger
Neutral
Mar 31, 2026
On March 31, 2026, Rallybio Corporation announced that Chief Medical Officer Steven Ryder, M.D., who has served in that role since January 2019, has left the company effective immediately. His departure comes as Rallybio prepares for a pending bus...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Rallybio to Merge with Candid Therapeutics in All-Stock Deal
Positive
Mar 2, 2026
Rallybio Corporation and Candid Therapeutics announced on March 2, 2026 that Rallybio will acquire Candid in an all-stock merger, after which the combined business will operate as Candid Therapeutics and list on Nasdaq under the ticker CDRX. The d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.